Internal: Archive

Swiss view Friday the 13th with trepidation

This content was published on Oct 12, 2000 A survey of 639 people published this week in Switzerland found that a substantial number associated Friday the 13th and the full moon with extraordinary occurrences. The full moon was seen as more ominous than the infamous Friday – a fifth of respondents said they had previously had strange experiences during a full moon. Of…

Forecast raised for SEZ

This content was published on Oct 12, 2000 The group, based in Zurich, expects sales in 2000 of around SFr190 million ($109 million), up from a previous forecast of SFr160-170 million. It has also upped its forecast for 2001, saying sales should be about SFr10 million higher at SFr260 million. Sales over the first nine months of this year more than tripled, coming…

Swiss admit to stalling on Milosevic accounts list

This content was published on Oct 12, 2000 The state secretariat for economic affairs on Thursday confirmed a report that appeared in the weekly publication, “Weltwoche”, claiming such a delay occurred. However, the authorities said their hesitation did not affect the eventual freezing of assets. The increase in the list of names targeted – from 300 to 600 – was only completed on…

Shares in main Swiss banks nosedive

This content was published on Oct 11, 2000 Zurich’s SMI slid 1.88 per cent to close down 147.20 points at 7665.40 on Wednesday, pulled down by the poor performance of banking sector stock. Credit Suisse shares were battered throughout the day’s trading, ending the session on the Zurich stock exchange down nearly nine per cent at SFr298. Shares in UBS closed down 6.46…

Novartis shareholders give green light to create Syngenta

This content was published on Oct 11, 2000 The shareholders, at an extraordinary general meeting in St Jakobs Hall in Basel, voted overwhelmingly in favour of the plan. AstraZeneca shareholders have still to approve the deal. Both parent companies are eager to divest themselves of their agribusinesses, which have suffered of late amid a global downturn in farming. The new company, called Syngenta,…

Ospel set to succeed Krauer as UBS chairman

This content was published on Oct 11, 2000 The board of directors is to propose at the annual shareholders’ meeting next April that the chief executive officer, Marcel Ospel (50), succeed him. Krauer joined UBS as interim chairman after the bank chalked up losses of SFr984 million in the 1998 scandal surrounding the Long-Term Capital Management Hedge Fund in the United States. Its…

Polar research is a hot topic for Swiss scientists

This content was published on Oct 11, 2000 Polar research may leave the general public cold or at least raise the question: why is land-locked Switzerland involved in such research at all? The Swiss Committee on Polar Research is holding a symposium with the aim of answering that question and explaining more about the work of Switzerland’s scientists. The disciplines represented at the…

Roche says provisions cover US vitamin deal

This content was published on Oct 11, 2000 The costs relate to a settlement agreed by Roche and five European and Japanese vitamin firms, which were charged with price fixing in the vitamin market. A Roche spokesman confirmed that the companies had agreed on the sum of $255 million to compensate states and indirect purchasers of vitamins. As part of the agreement, Roche…

Sales slow at Novartis

This content was published on Oct 11, 2000 Excluding businesses divested in 1999 and the discontinuing Agribusiness activities to be spun off in mid-November, the company’s healthcare division posted nine month sales of SFr21.3 billion, an increase of 15 per cent in Swiss francs or seven per cent in local currencies. That marked a minor slowdown from the eight per cent rise in…

Flat growth for Givaudan

This content was published on Oct 11, 2000 In local currencies sales were flat over the period, but results were in line with market expectations. “Barring unforeseen events, Givaudan expects a good net result for the full year,” the company said in a statement. It gave no profit figures for the period. The company said its strongest growth for the flavours and fragrances…

Internal: Archive

Popular Stories

Most Discussed

Sign in and personalize Swissinfo

Internal: Archive

More

Swiss view Friday the 13th with trepidation

More

Forecast raised for SEZ

More

Swiss admit to stalling on Milosevic accounts list

More

Shares in main Swiss banks nosedive

More

Novartis shareholders give green light to create Syngenta

More

Ospel set to succeed Krauer as UBS chairman

More

Polar research is a hot topic for Swiss scientists

More

Roche says provisions cover US vitamin deal

More

Sales slow at Novartis

More

Flat growth for Givaudan

Popular Stories

Most Discussed